Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark.
Unit of Statistics and Pharmaco-epidemiology, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark.
Gynecol Oncol. 2018 Dec;151(3):513-518. doi: 10.1016/j.ygyno.2018.09.022. Epub 2018 Sep 21.
Few studies have examined ovarian borderline tumor (BOT) risk associated with analgesics, and with inconclusive findings. The aim was to examine serous borderline tumor (SBT) or mucinous borderline tumor (MBT) risk associated with use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs).
We identified all women with SBTs or MBTs in the Danish Pathology Data Bank, 1997-2015. Using risk-set sampling, we randomly selected 15 controls per case. We excluded women with previous cancer (except non-melanoma skin cancer) and controls with bilateral oophorectomy/salpingo-oophorectomy. Information on redeemed prescriptions of medications/confounders was identified from nationwide registries. We used conditional logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
We observed a decreased MBT risk among recent paracetamol users (OR = 0.77; 95% CI: 0.60-0.98), but no association with SBTs. Regarding non-aspirin NSAIDs, we found an increased SBT risk with recent (OR = 1.29; 95% CI: 1.11-1.51) and former use (OR = 1.19; 95% CI: 1.04-1.37), and an elevated MBT risk with recent use (OR = 1.14; 95% CI: 0.97-1.33). Low-dose aspirin use did not seem related with SBT risk, and the association with MBTs was unclear.
No strong associations between the examined medications and BOTs were observed. However, our nationwide case-control study may suggest that recent paracetamol use could have a chemopreventive effect on MBTs, whereas neither low-dose aspirin nor non-aspirin NSAIDs use seem to protect against SBTs or MBTs. Larger studies are needed to firmly establish a potential association between these medications and BOT risk.
很少有研究调查过镇痛药与卵巢交界性肿瘤（BOT）风险之间的关系，且研究结果并不明确。本研究旨在探讨与使用扑热息痛、低剂量阿司匹林或非阿司匹林非甾体抗炎药（NSAIDs）相关的浆液性交界性肿瘤（SBT）或黏液性交界性肿瘤（MBT）风险。
我们在丹麦病理数据库中确定了所有患有 SBT 或 MBT 的女性，时间范围为 1997 年至 2015 年。通过风险集抽样，我们为每个病例随机选择了 15 名对照。我们排除了有既往癌症（除非黑色素瘤皮肤癌外）的女性和双侧卵巢切除术/输卵管卵巢切除术的对照。从全国性登记册中获取已购药物/混杂因素的信息。我们使用条件逻辑回归来估计调整后的比值比（OR）和 95%置信区间（CI）。
我们观察到近期使用扑热息痛的 MBT 风险降低（OR=0.77；95%CI：0.60-0.98），但与 SBT 无关。关于非阿司匹林 NSAIDs，我们发现近期（OR=1.29；95%CI：1.11-1.51）和既往使用（OR=1.19；95%CI：1.04-1.37）与 SBT 风险增加有关，近期使用与 MBT 风险增加有关（OR=1.14；95%CI：0.97-1.33）。低剂量阿司匹林的使用似乎与 SBT 风险无关，而与 MBTs 的关联尚不清楚。
我们没有发现所检查的药物与 BOT 之间存在强烈的关联。然而，我们的全国性病例对照研究可能表明，近期使用扑热息痛可能对 MBT 具有化学预防作用，而低剂量阿司匹林或非阿司匹林 NSAIDs 的使用似乎不能预防 SBT 或 MBT。需要更大规模的研究来确定这些药物与 BOT 风险之间的潜在关联。
